{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:30:33Z","timestamp":1749043833110},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11096-016-0308-3","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T16:45:39Z","timestamp":1461861939000},"page":"908-914","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis"],"prefix":"10.1007","volume":"38","author":[{"given":"Takafumi","family":"Nakano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Irie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Imakyure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujiro","family":"Futagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"key":"308_CR1","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM consensus conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992;101:1644\u201355.","journal-title":"Chest"},{"key":"308_CR2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000329460","volume":"11","author":"V Mylona","year":"2011","unstructured":"Mylona V, Koussoulas V, Tzivras D, Makrygiannis E, Georgopoulou P, Koratzanis G, et al. Changes in adaptive and innate immunity in patients with acute pancreatitis and systemic inflammatory response syndrome. Pancreatology. 2011;11:475\u201381.","journal-title":"Pancreatology"},{"key":"308_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00134-007-0934-2","volume":"34","author":"RP Dellinger","year":"2008","unstructured":"Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17\u201360.","journal-title":"Intensive Care Med"},{"key":"308_CR4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","volume":"136","author":"A Kumar","year":"2009","unstructured":"Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136:1237\u201348.","journal-title":"Chest"},{"key":"308_CR5","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dkq516","volume":"66","author":"C McKenzie","year":"2011","unstructured":"McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother. 2011;66:ii25\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"308_CR6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijantimicag.2006.10.003","volume":"29","author":"J Brauers","year":"2007","unstructured":"Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Int J Antimicrob Agents. 2007;29:322\u20135.","journal-title":"Int J Antimicrob Agents"},{"key":"308_CR7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.10.018","volume":"37","author":"SH Lin","year":"2011","unstructured":"Lin SH, Lai CC, Tan CK, Liao WH, Hsueh PR. Comparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int J Antimicrob Agents. 2011;37:179\u201381.","journal-title":"Int J Antimicrob Agents"},{"key":"308_CR8","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","volume":"53","author":"S Svetitsky","year":"2009","unstructured":"Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:4069\u201379.","journal-title":"Antimicrob Agents Chemother"},{"key":"308_CR9","volume-title":"The JAID\/JSC guide to clinical management of infectious diseases","author":"The Japanese Association for Infectious Diseases","year":"2014","unstructured":"The Japanese Association for Infectious Diseases, the Japanese Society of Chemotherapy. The JAID\/JSC guide to clinical management of infectious diseases. Tokyo: Sanposha Printing; 2014."},{"key":"308_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10156-010-0038-8","volume":"16","author":"K Matsumoto","year":"2010","unstructured":"Matsumoto K, Kanazawa N, Ikawa K, Fukamizu T, Shigemi A, Yaji K, et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3\u00a0days: a retrospective study in patients with MRSA infections. J Infect Chemother. 2010;16:193\u20139.","journal-title":"J Infect Chemother"},{"key":"308_CR11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/45.6.835","volume":"45","author":"I Harding","year":"2000","unstructured":"Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000;45:835\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"308_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","volume":"39","author":"AP Wilson","year":"2000","unstructured":"Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"308_CR13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00134-006-0136-3","volume":"32","author":"O Mimoz","year":"2006","unstructured":"Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, et al. Steady state trough serum and epithelial lining fluid concentrations of teicoplanin 12\u00a0mg\/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:775\u20139.","journal-title":"Intensive Care Med"},{"key":"308_CR14","volume-title":"Clinical practice guidelines for TDM of antimicrobial agents","author":"The Japanese Society of Chemotherapy","year":"2012","unstructured":"The Japanese Society of Chemotherapy, the Japanese Society of Therapeutic Drug Monitoring. Clinical practice guidelines for TDM of antimicrobial agents. Tokyo: Kyorinsha; 2012."},{"key":"308_CR15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.5649\/jjphcs.34.662","volume":"34","author":"S Noguchi","year":"2008","unstructured":"Noguchi S, Ueda Y, Shibuya M, Konomatsu A, Ito A, Shimada Y, et al. Effectiveness of treatment strategy using high-dose teicoplanin (TEIC) in emergency and critical care medicine. Jpn J Pharm Health Care Sci. 2008;34:662\u201370.","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"308_CR16","first-page":"14","volume":"26","author":"M Mitsuda","year":"2009","unstructured":"Mitsuda M, Noguchi K, Kosako K, Tsuji N, Nogiwa T, Matsubara F, et al. Clinical efficacy of teicoplanin with high-dose loading regimen for MRSA infection. Jpn J TDM. 2009;26:14\u201320.","journal-title":"Jpn J TDM"},{"key":"308_CR17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10156-011-0325-z","volume":"18","author":"T Ueda","year":"2012","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Tsuchida T, et al. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration. J Infect Chemother. 2012;18:296\u2013302.","journal-title":"J Infect Chemother"},{"key":"308_CR18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1248\/yakushi.14-00185","volume":"134","author":"T Nakano","year":"2014","unstructured":"Nakano T, Nakamura Y, Togawa A, Takata T, Ishikura H, Mishima K, et al. Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score. Yakugaku Zasshi. 2014;134:1367\u201373.","journal-title":"Yakugaku Zasshi"},{"key":"308_CR19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1248\/bpb1978.8.246","volume":"8","author":"K Yamaoka","year":"1985","unstructured":"Yamaoka K, Nakagawa T, Tanaka H, Yasuhara M, Okumura K, Hori R, et al. A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers. J Pharmacobiodyn. 1985;8:246\u201356.","journal-title":"J Pharmacobiodyn"},{"key":"308_CR20","first-page":"1","volume":"54","author":"K Nakayama","year":"2006","unstructured":"Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006;54:1\u20136.","journal-title":"Jpn J Chemother"},{"key":"308_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"308_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2014.01.015","volume":"79","author":"S Blot","year":"2014","unstructured":"Blot S, Lipman J, Roberts DM, Roberts JA. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis. 2014;79:77\u201384.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"308_CR23","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00134-013-2909-9","volume":"39","author":"Y Shimamoto","year":"2013","unstructured":"Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013;39:1247\u201352.","journal-title":"Intensive Care Med"},{"key":"308_CR24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcrc.2014.03.015","volume":"29","author":"GP Otto","year":"2014","unstructured":"Otto GP, Sossdorf M, Breuel H, Schlattmann P, Bayer O, Claus RA, et al. Renal outcome after vancomycin treatment and renal replacement therapy in patients with severe sepsis and septic shock: a retrospective study. J Crit Care. 2014;29:656\u201361.","journal-title":"J Crit Care"},{"key":"308_CR25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/jcpt.12088","volume":"38","author":"R Minkut\u0117","year":"2013","unstructured":"Minkut\u0117 R, Briedis V, Steponavi\u010di\u016bt\u0117 R, Vitkauskien\u0117 A, Ma\u010diulaitis R. Augmented renal clearance\u2013an evolving risk factor to consider during the treatment with vancomycin. J Clin Pharm Ther. 2013;38:462\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"308_CR26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijantimicag.2012.05.010","volume":"40","author":"U Tr\u00f6ger","year":"2012","unstructured":"Tr\u00f6ger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-B\u00f6ger SM. Decreased meropenem levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents. 2012;40:370\u20132.","journal-title":"Int J Antimicrob Agents"},{"key":"308_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","volume":"142","author":"AA Udy","year":"2012","unstructured":"Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30\u20139.","journal-title":"Chest"},{"key":"308_CR28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1248\/yakushi.14-00214","volume":"135","author":"J Irikuchi","year":"2015","unstructured":"Irikuchi J, Imai T, Yoshida Y, Orii T. Influence of systemic inflammatory response syndrome on the pharmacokinetics of vancomycin. Yakugaku Zasshi. 2015;135:745\u201351.","journal-title":"Yakugaku Zasshi"},{"key":"308_CR29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0310057X0203000203","volume":"30","author":"M Pinder","year":"2002","unstructured":"Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care. 2002;30:134\u201344.","journal-title":"Anaesth Intensive Care"},{"key":"308_CR30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.31.10.1600","volume":"31","author":"Y Domart","year":"1987","unstructured":"Domart Y, Pierre C, Clair B, Garaud JJ, Regnier B, Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother. 1987;31:1600\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"308_CR31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/dkl017","volume":"57","author":"CG Gemmell","year":"2006","unstructured":"Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57:589\u2013608.","journal-title":"J Antimicrob Chemother"},{"key":"308_CR32","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dkq266","volume":"65","author":"CM Tobin","year":"2010","unstructured":"Tobin CM, Lovering AM, Sweeney E, MacGowan AP. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J Antimicrob Chemother. 2010;65:2155\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"308_CR33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2008.05.012","volume":"32","author":"AJ Brink","year":"2008","unstructured":"Brink AJ, Richards GA, Cummins RR, Lambson J, Gauteng Understanding Teicoplanin Serum levels (GUTS) Study Group. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalized patients treated for sepsis. Int J Antimicrob Agents. 2008;32:455\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"308_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-200443060-00004","volume":"43","author":"F Pea","year":"2004","unstructured":"Pea F, Viale P, Candoni A, Pavan F, Pageni L, Dasini D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43:405\u201315.","journal-title":"Clin Pharmacokinet"},{"key":"308_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","volume":"20","author":"T Ueda","year":"2014","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Komatsu M, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014;20:43\u20137.","journal-title":"J Infect Chemother"},{"key":"308_CR36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1248\/bpb.b12-00911","volume":"36","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Kanazawa N, Watanabe E, Yokoyama Y, Fukamizu T, Shimodozono Y, et al. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections. Biol Pharm Bull. 2013;36:1024\u20136.","journal-title":"Biol Pharm Bull"},{"key":"308_CR37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2015.02.002","volume":"21","author":"A Nakamura","year":"2015","unstructured":"Nakamura A, Takasu O, Sakai Y, Sakamoto T, Yamashita N, Mori S, et al. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections. J Infect Chemother. 2015;21:449\u201355.","journal-title":"J Infect Chemother"},{"key":"308_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkp147","volume":"64","author":"E Lamont","year":"2009","unstructured":"Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother. 2009;64:181\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"308_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1473-3099(01)00093-7","volume":"1","author":"T Poll van der","year":"2001","unstructured":"van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis. 2001;1:165\u201374.","journal-title":"Lancet Infect Dis"},{"key":"308_CR40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00005373-199404000-00002","volume":"36","author":"P Gosling","year":"1994","unstructured":"Gosling P, Sanghera K, Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma. 1994;36:477\u201381.","journal-title":"J Trauma"},{"key":"308_CR41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840\u201351.","journal-title":"Crit Care Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-016-0308-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0308-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T03:25:53Z","timestamp":1567826753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-016-0308-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,28]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s11096-016-0308-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,28]]}}}